KLRS
KalarisยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
KLRS Profile
Kalaris Therapeutics, Inc.
A late-clinical stage allogeneic T-cell immunotherapy company that develops allogeneic, off-the-shelf VST therapies for devastating viral diseases
628 Middlefield Rd., Palo Alto, California 94301
--
Kalaris Therapeutics, Inc., established on August 16, 2013, is a Delaware limited liability company. The company is a leading clinical late-stage cell therapy company developing highly innovative allogeneic T-cell therapies to treat and prevent devastating viral diseases. The company's innovative and proprietary virus-specific T cell (VST) therapeutic platform enables the generation of ready-made VSTs designed to restore immunity in patients with T cell deficiency.
